DTC
CLDX icon

Deep Track Capital’s Celldex Therapeutics CLDX Stock Holding History

Deep Track Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109M Buy
2,939,151
+1,655,172
+129% +$53.5M 1.59% 27
2026
Q1 		$40.7M Sell
1,283,979
-616,759
-32% -$16.8M 0.67% 37
2025
Q4 		$51.6M Sell
1,900,738
-99,262
-5% -$2.61M 0.92% 28
2025
Q3 		$51.7M Hold
2,000,000
– – 1.44% 25
2025
Q2 		$40.7M Hold
2,000,000
– – 1.31% 25
2025
Q1 		$36.3M Buy
2,000,000
+459,868
+30% +$10.3M 1.18% 23
2024
Q4 		$38.9M Buy
+1,540,132
New +$41.8M 1.45% 23

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Deep Track Capital's CLDX Position: Q2 2026 in Review

Deep Track Capital increased its Celldex Therapeutics (CLDX) stake by 129% in Q2 2026, buying an estimated $53.5M and bringing the position to 2,939,151 shares worth $109M. The position accounts for 1.59% of the portfolio, ranked #27.

Deep Track Capital first reported a position in CLDX in Q4 2024 and has held it in 7 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Deep Track Capital held 2,939,151 shares of Celldex Therapeutics worth $109M as of Q2 2026.
  • Deep Track Capital bought 1,655,172 Celldex Therapeutics shares in Q2 2026, an estimated $53.5M.
  • Celldex Therapeutics made up 1.59% of Deep Track Capital's portfolio in Q2 2026, its #27 holding.
  • Deep Track Capital first reported a position in Celldex Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.